<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34284248</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8952</ISSN><JournalIssue CitedMedium="Internet"><Volume>132</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology</Title><ISOAbbreviation>Clin Neurophysiol</ISOAbbreviation></Journal><ArticleTitle>Split-hand index: A diagnostic and prognostic marker in amyotrophic lateral sclerosis across varying regions of onset.</ArticleTitle><Pagination><StartPage>2130</StartPage><EndPage>2135</EndPage><MedlinePgn>2130-2135</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clinph.2021.06.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1388-2457(21)00619-2</ELocationID><Abstract><AbstractText Label="OBJECTIVE">The split-hand index (SI), a reliable diagnostic marker of amyotrophic lateral sclerosis (ALS), was prospectively assessed for differences across ALS subtypes and between the onset side of clinical symptoms or the dominant and contralateral sides. In addition, the prognostic utility of the SI was longitudinally assessed.</AbstractText><AbstractText Label="METHODS">Two hundred and forty-five ALS patients underwent measurement of SI on both sides compared with 126 neuromuscular mimic disorders (NMD). A subset of patients (N&#xa0;=&#xa0;45) underwent longitudinal assessment of SI.</AbstractText><AbstractText Label="RESULTS">The SI was significantly reduced (SI <sub>RIGHT ALS</sub> 5.47(4.2), SI<sub>NMD</sub> 9.0 (5.0); P&#xa0;&lt;&#xa0;0.001; SI<sub>LEFT ALS</sub> 5.5 (4.1), SI <sub>NMD</sub> 9.4 (5.0), P&#xa0;&lt;&#xa0;0.001) on both sides in all ALS patients with prominent reduction on the onset side in upper limb onset ALS (SI <sub>RIGHT</sub> P&#xa0;&lt;&#xa0;0.001; SI <sub>LEFT</sub> P&#xa0;&lt;&#xa0;0.05) and in Awaji definite/probable diagnostic category (SI <sub>RIGHT</sub> P&#xa0;&lt;&#xa0;0.05; SI <sub>LEFT</sub> P&#xa0;&lt;&#xa0;0.05). Longitudinal studies disclosed that the rate of SI decline correlated with the decline in ALSFRS-R (r&#xa0;=&#xa0;0.21, P&#xa0;&lt;&#xa0;0.05).</AbstractText><AbstractText Label="CONCLUSION">The SI is reduced in all ALS subtypes most prominently in upper limb onset disease, on the side of clinical onset, and in patients with Awaji definite/probable diagnostic category.</AbstractText><AbstractText Label="SIGNIFICANCE">The split-hand index is a reliable diagnostic and outcome biomarker across ALS subtypes and may have potential utility in a clinical trial setting, although further multicenter studies are required to confirm this.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hannaford</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Westmead Hospital, Sydney, Australia; University of Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higashihara</LastName><ForeName>Mana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Westmead Hospital, Sydney, Australia; Tokyo Metropolitan Geriatric Hospital, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavey</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Westmead Hospital, Sydney, Australia; University of Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Bos</LastName><ForeName>Mehdi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Westmead Hospital, Sydney, Australia; University of Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geevasinga</LastName><ForeName>Nimeshan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Westmead Hospital, Sydney, Australia; University of Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vucic</LastName><ForeName>Steve</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Westmead Hospital, Sydney, Australia; University of Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menon</LastName><ForeName>Parvathi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Westmead Hospital, Sydney, Australia; University of Sydney, Australia. Electronic address: parvathi.menon@sydney.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Clin Neurophysiol</MedlineTA><NlmUniqueID>100883319</NlmUniqueID><ISSNLinking>1388-2457</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006225" MajorTopicYN="N">Hand</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053580" MajorTopicYN="N">Muscle Strength</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009460" MajorTopicYN="N">Neurologic Examination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS subtypes</Keyword><Keyword MajorTopicYN="N">Region of clinical disease onset</Keyword><Keyword MajorTopicYN="N">Split-hand index</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>20</Day><Hour>20</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34284248</ArticleId><ArticleId IdType="doi">10.1016/j.clinph.2021.06.008</ArticleId><ArticleId IdType="pii">S1388-2457(21)00619-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>